Working data console · India-focused biopharma platform

India Biopharma Atlas

A product of Avyakt AI

Twenty-two government, exchange, media, and international sources, extracted and joined into one queryable base — trial registrations, patent filings, drug approvals, medicine ceiling prices, state drug-license actions across Gujarat, Jharkhand and Delhi, listed pharma and insurance company financials and filings, live news coverage, a national insurance scheme, disease burden, district health infrastructure, state-level economic output, population and its decadal growth, and the geography that ties them together.

Where the data actually comes from

Every source checked by hand this build — not assumed from documentation. Color is access difficulty, not data quality; several sources marked open turned out to hide real friction underneath.

Free & open Free UI, no confirmed bulk path Needs an agreement / MoU Paid / licensed

By domain

A sample of what's actually loaded, not a mock-up — every row below is a real record pulled this build.

Pharma & biotech · all 233 listed companies

Financial ratios from a point-in-time screener export, joined against each company's own BSE filing history. Click a column header to sort. Filing counts are the last 3 years.

# Company Mkt Cap (₹cr) P/E ROCE % ROE % YoY Qtr Profit Debt/Eq Filings

Recent filings · pharma & biotech

Pulled from each company's own BSE corporate-announcement archive — annual reports, concall transcripts, investor decks, results, AGM notices, insider-trading disclosures, corporate actions. Metadata + a direct PDF link, not the document content.

Insurance · 15 major listed insurers

Life, general, and health insurers, verified individually against BSE's own company search — not a screener export, since none exists for this sector. Sub-category is BSE's own classification. P/E, EPS, and ROE use consolidated figures where standalone isn't available (marked *).

Company Category Price (₹) P/E EPS ROE % Filings

Recent filings · insurance

Same BSE archive pattern as the pharma companies tab, extended with insurance-specific categories — embedded value / VNB, solvency, and claim-settlement disclosures — where insurers file them as standalone announcements.

India pharma, biotech & clinical-trial news

Aggregated via Google News RSS across Times of India, Hindustan Times, Firstpost, The Hindu, Business Standard, and ~100 more publishers — a snapshot of the last 14 days, not a live feed. Links go to the original article. Company and topic tags are computed by matching headline text, not AI-generated.

Most-mentioned tracked companies

Headlines cross-referenced against this dashboard's own verified company lists (233 pharma/biotech + 15 insurers).

Articles

Population · state & district

Census 2011 (the most recent full census — 2021's was postponed and hasn't happened). 612 of 784 current districts matched; the rest were created by post-2011 splits. 612 of those also carry a 2001→2011 growth rate (Census table A-02, decadal population back to 1901). 608 also carry Sub Centre/PHC/CHC/hospital counts (Rural Health Statistics 2021-22). Type to filter, click a column to sort.

District State Population (2011) Density /km² Area (km²) Growth '01–'11 PHCs CHCs Dist. Hospitals

Disease & nutrition burden — ranked

NFHS-5 (2019-21), state level. Ranked highest to lowest prevalence. "Disease" here means the 15 real, published conditions this survey covers — anemia and malnutrition (by severity, gender, and life stage) — not a general disease registry. Diabetes and hypertension genuinely aren't in this data source; see the note below.

Pick a state for its own ranking:

Age & gender patterns

Two distinct, real signals — not merged into one, since they measure different things.

By gender: every condition above is already split by women/men (and children separately) — e.g. anemia runs far higher in women than men in every state checked. Use the ranked lists above.

By age: NFHS-5 doesn't publish a fine-grained age curve — only women 15-49, men 15-49, and children under 5 as life-stage bands. The closest real age-banded data this platform has is PM-JAY hospital-admission share by age bracket (Overview tab) — that's insurance-scheme utilization, not disease prevalence, and shouldn't be read as the same thing.

What's not available here

Medicine consumption data and which pharma companies are strongest in a given region were both explicitly requested and are both, honestly, not free/public data:
  • Medicine consumption (volume sold, by region) is what IQVIA and PharmaTrac sell as a commercial product — both already confirmed in this platform's own source registry as paid/licensed with no public data portal. NPPA's ceiling prices (Overview tab) are a regulatory maximum price, set nationally, not a consumption or sales figure.
  • Regional pharma market strength (which company dominates which state/district) is the same category of data — IQVIA's core commercial product is exactly this. No free equivalent exists. The closest honest proxy this platform has is company-level financials and BSE filings (Companies tab) and national drug-approval counts (Overview tab) — neither is regional.

What the data actually says

19 findings computed directly against the loaded tables, not asserted — each one is a real query result, not a talking point. Several cut against the obvious assumption.

Ask the data

A structured lookup over the exact dataset loaded on this page — trials, patents, drug approvals, PM-JAY, disease indicators, and the source registry above. No AI, no server calls, matches by keyword rather than free-form language.

Ask me anything about the trials, patents, drug approvals, PM-JAY, or disease data loaded on this dashboard.

Articles for pharma companies

Strategy and competitive-intelligence reads, each built from the real tables loaded on this dashboard — not commentary, every figure traces back to a query you could re-run yourself.

About

India Biopharma Atlas is a product of Avyakt AI.

Avyakt AI is a specialized artificial intelligence consulting and engineering firm that builds production-grade machine learning and generative AI systems for regulated industries like manufacturing, shipping, and life sciences.

Write to us at hello@avyaktai.com

avyaktai.com →